Patents by Inventor Mark A. Kay

Mark A. Kay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8124407
    Abstract: Circular nucleic acid vectors that provide for persistently high levels of protein expression are provided. The circular vectors of the subject invention are characterized by being devoid of expression-silencing bacterial sequences, where in many embodiments the subject vectors include a unidirectional site-specific recombination product hybrid sequence in addition to an expression cassette. Also provided are methods of using the subject vectors for introduction of a nucleic acid, e.g., an expression cassette, into a target cell, as well as preparations for use in practicing such methods. The subject methods and compositions find use in a variety of different applications, including both research and therapeutic applications. Also provided is a highly efficient and readily scalable method for producing the vectors employed in the subject methods, as well as reagents and kits/systems for practicing the same.
    Type: Grant
    Filed: January 13, 2011
    Date of Patent: February 28, 2012
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Mark A. Kay, Zhi-Ying Chen
  • Publication number: 20120004279
    Abstract: Compositions and methods for modulating transcription by RNA polymerases are described.
    Type: Application
    Filed: September 2, 2011
    Publication date: January 5, 2012
    Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Mark A. Kay, Dirk Haussecker, Dan Cao
  • Patent number: 8067014
    Abstract: Recombinant adeno-associated viral (AAV) capsid proteins are provided. Methods for generating the recombinant adeno-associated viral capsid proteins and a library from which the capsids are selected are also provided.
    Type: Grant
    Filed: August 10, 2009
    Date of Patent: November 29, 2011
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Mark Kay, Dirk Grimm
  • Patent number: 8034922
    Abstract: Compositions and methods for modulating transcription by RNA polymerases are described.
    Type: Grant
    Filed: August 21, 2009
    Date of Patent: October 11, 2011
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Mark A. Kay, Dirk Haussecker, Dan Cao
  • Publication number: 20110244566
    Abstract: Human somatic cells are reprogrammed to become induced pluripotent stem cells (iPS cells) by the introduction of a minicircle DNA vector. Cells of interest include adipose stem cells.
    Type: Application
    Filed: February 1, 2011
    Publication date: October 6, 2011
    Inventors: Joseph Wu, Michael T. Longaker, Mark A. Kay, Ning Sung, FangJun Jia, Zhi-Ying Chen, Nicholas Panetta, Deepak Gupta
  • Patent number: 8008468
    Abstract: The present invention provides compositions and methods suitable for RNAi specifically in the liver so as to treat diseases or disorders.
    Type: Grant
    Filed: February 16, 2006
    Date of Patent: August 30, 2011
    Assignee: Benitec, Inc.
    Inventors: Petrus W. Roelvink, David A. Suhy, Alexander A. Kolykhalov, Mark A. Kay, Jeffery C. Giering
  • Patent number: 7985739
    Abstract: Methods and compositions for introducing a nucleic acid into the genome of a cell are provided. In the subject methods, a Sleeping Beauty transposon that includes the nucleic acid is introduced into the cell along with a source of a mutant Sleeping Beauty transposase that provides for enhanced integration as compared to the wild-type Sleeping Beauty transposase having an amino acid sequence as shown in SEQ ID NO:01. Introduction of the mutant Sleeping Beauty Transposase and transposon results in integration of the nucleic acid into the cell genome. Also provided are mutant transposases and transposons, as well as systems and kits thereof, that find use in practicing the subject methods. The subject methods and compositions find use in a variety of different applications.
    Type: Grant
    Filed: June 3, 2004
    Date of Patent: July 26, 2011
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Mark A. Kay, Stephen Yant
  • Publication number: 20110126306
    Abstract: Circular nucleic acid vectors that provide for persistently high levels of protein expression are provided. The circular vectors of the subject invention are to characterized by being devoid of expression-silencing bacterial sequences, where in many embodiments the subject vectors include a unidirectional site-specific recombination product hybrid sequence in addition to an expression cassette. Also provided are methods of using the subject vectors for introduction of a nucleic acid, e.g., an expression cassette, into a target cell, as well as preparations for use in practicing such methods. The subject methods and compositions find use in a variety of different applications, including both research and therapeutic applications. Also provided is a highly efficient and readily scalable method for producing the vectors employed in the subject methods, as well as reagents and kits/systems for practicing the same.
    Type: Application
    Filed: January 13, 2011
    Publication date: May 26, 2011
    Inventors: Mark A. Kay, Zhi-Ying Chen
  • Publication number: 20110118333
    Abstract: Compositions and methods are provided for the treatment of an ischemic cardiovascular condition by providing a patient with a novel non-viral minicircle DNA vector comprising polynucleotide sequences that potentiate HIF-1 activity, including RNAi or antisense agents selective for proteins involved in HIF1 inactivation.
    Type: Application
    Filed: October 22, 2010
    Publication date: May 19, 2011
    Inventors: Joseph Wu, Mark A. Kay, Mei Huang, Zhi-Ying Chen
  • Patent number: 7897380
    Abstract: Circular nucleic acid vectors that provide for persistently high levels of protein expression are provided. The circular vectors of the subject invention are characterized by being devoid of expression-silencing bacterial sequences, where in many embodiments the subject vectors include a unidirectional site-specific recombination product hybrid sequence in addition to an expression cassette. Also provided are methods of using the subject vectors for introduction of a nucleic acid, e.g., an expression cassette, into a target cell, as well as preparations for use in practicing such methods. The subject methods and compositions find use in a variety of different applications, including both research and therapeutic applications. Also provided is a highly efficient and readily scalable method for producing the vectors employed in the subject methods, as well as reagents and kits/systems for practicing the same.
    Type: Grant
    Filed: August 28, 2003
    Date of Patent: March 1, 2011
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Mark A. Kay, Zhi-Ying Chen
  • Publication number: 20100325747
    Abstract: Described herein is a method of expanding human hepatocytes in vivo using an immunodeficient mouse which is further deficient in fumarylacetoacetate hydrolase (Fah). The method comprises transplanting human hepatocytes into the immunodeficient and Fah-deficient mice, allowing the hepatocytes to expand and collecting the expanded human hepatocytes. The method also allows serial transplantation of the human hepatocytes into secondary, tertiary, quaternary or additional mice. Also provided are mutant mice comprising homozygous deletions or point mutations in the Fah, Rag2 and Il2rg genes.
    Type: Application
    Filed: June 5, 2008
    Publication date: December 23, 2010
    Inventors: Markus Grompe, Hisaya Azuma, Muhsen Al-Dhalimy, Mark A. Kay
  • Publication number: 20100099740
    Abstract: Methods and compositions are provided for modulating, e.g., reducing, expression of a target sequence in mammals and mammalian cells in vivo. In the subject methods, an effective amount of an RNAi agent, e.g., an interfering ribonucleic acid (such as an siRNA or shRNA) is introduced into a target cell, e.g., by being administered to a mammal that includes the target cell, e.g., via intravascular injection. Also provided are RNAi agent pharmaceutical preparations for use in the subject methods. The subject methods and compositions find use in a variety of different applications, including academic and therapeutic applications.
    Type: Application
    Filed: October 8, 2009
    Publication date: April 22, 2010
    Inventors: Mark A. Kay, Anton McCaffrey
  • Publication number: 20100075401
    Abstract: The present invention provides minicircle nucleic acid vector formulations for use in administering to a subject, wherein the minicircle nucleic acid vectors include a polynucleotide of interest, a product hybrid sequence of a unidirectional site-specific recombinase, and are devoid of plasmid backbone bacterial DNA sequences. Also provided are methods of producing the subject formulations as well as methods for administering the minicircle nucleic acid vector formulations to a subject. The subject methods and compositions find use in a variety of different applications, including both research and therapeutic applications.
    Type: Application
    Filed: July 2, 2009
    Publication date: March 25, 2010
    Inventors: Zhi-Ying Chen, Mark A. Kay
  • Publication number: 20100069464
    Abstract: Compositions and methods for modulating transcription by RNA polymerases are described.
    Type: Application
    Filed: August 21, 2009
    Publication date: March 18, 2010
    Applicant: Board of Trustees of the Leland Stanford Junior University
    Inventors: Mark A. Kay, Dirk Haussecker, Dan Cao
  • Publication number: 20100047174
    Abstract: Recombinant adeno-associated viral (AAV) capsid proteins are provided. Methods for generating the recombinant adeno-associated viral capsid proteins and a library from which the capsids are selected are also provided.
    Type: Application
    Filed: August 10, 2009
    Publication date: February 25, 2010
    Inventors: Mark Kay, Dirk Grimm
  • Publication number: 20090264505
    Abstract: Methods and compositions are provided for modulating, e.g., reducing, expression of a target sequence in mammals and mammalian cells. In the subject methods, an effective amount of an RNAi agent, e.g., an interfering ribonucleic acid (such as an siRNA or shRNA) or a transcription template thereof, e.g., a DNA encoding an shRNA, is introduced into a target cell, e.g., by being administered to a mammal that includes the target cell, e.g., via a hydrodynamic administration protocol. Also provided are RNAi agent pharmaceutical preparations for use in the subject methods. The subject methods and compositions find use in a variety of different applications, including academic and therapeutic applications.
    Type: Application
    Filed: February 9, 2009
    Publication date: October 22, 2009
    Inventors: MARK A. KAY, ANTON MCCAFFREY
  • Patent number: 7588772
    Abstract: Recombinant adeno-associated viral (AAV) capsid proteins are provided. Methods for generating the recombinant adeno-associated viral capsid proteins and a library from which the capsids are selected are also provided.
    Type: Grant
    Filed: March 30, 2007
    Date of Patent: September 15, 2009
    Assignee: Board of Trustees of the Leland Stamford Junior University
    Inventors: Mark Kay, Dirk Grimm
  • Patent number: 7351813
    Abstract: In one aspect, the present invention provides nucleic acid expression cassettes that are predominantly expressed in the mammalian liver. The present invention also provides vectors comprising a nucleic acid expression cassette that is predominantly expressed in the mammalian liver. The present invention also provides methods of ameliorating the symptoms of a disease, the methods including the steps of introducing into the liver of a mammalian subject a vector comprising a nucleic acid expression cassette that encodes a polypeptide, and expressing a therapeutic amount of the polypeptide in the liver.
    Type: Grant
    Filed: June 18, 2001
    Date of Patent: April 1, 2008
    Assignees: The Board of Trustees of the Leland Stanford Junior University, University of Washington
    Inventors: Carol H. Miao, Mark A. Kay
  • Patent number: D611112
    Type: Grant
    Filed: April 4, 2008
    Date of Patent: March 2, 2010
    Inventor: Ira Mark Kay
  • Patent number: D611113
    Type: Grant
    Filed: April 4, 2008
    Date of Patent: March 2, 2010
    Inventor: Ira Mark Kay